Yao Shangkun, the chairman of Guoxiong Capital, emphasized that China's technological prowess in the realm of life sciences is already among the world's elite. However, he noted that scientists embarking on entrepreneurial ventures must transcend the conventional boundaries of financial investment. Yao advocates for a holistic empowerment model, spanning from '-1 to 1', which initiates with patent strategy formulation during the research paper phase and extends comprehensive support through drug development to eventual commercialization. This approach aims to address the scientists' lack of experience and resources.